-
End to US government shutdown in sight as stopgap bill advances to House
-
'Western tech dominance fading' at Lisbon's Web Summit
-
Asian stocks rise as record US shutdown nears end
-
'Joy to beloved motherland': N.Korea football glory fuels propaganda
-
Taiwan coastguard faces China's might near frontline islands
-
Concentration of corporate power a 'huge' concern: UN rights chief
-
Indian forensic teams scour deadly Delhi car explosion
-
Trump says firebrand ally Greene has 'lost her way' after criticism
-
Show shines light on Mormons' unique place in US culture
-
Ukraine, China's critical mineral dominance, on agenda as G7 meets
-
AI agents open door to new hacking threats
-
Syria joins alliance against Islamic State after White House talks
-
As COP30 opens, urban Amazon residents swelter
-
NHL unveils new Zurich office as part of global push
-
Szalay wins Booker Prize for tortured tale of masculinity
-
'Netflix House' marks streaming giant's first theme park
-
UN warns of rough winter ahead for refugees
-
Brazil's 'action agenda' at COP30 takes shape
-
Trump threatens $1 billion action as BBC apologises for edit error
-
Sinner dominates injury-hit Auger-Aliassime in ATP Finals opener
-
Trump hails Syria's 'tough' ex-jihadist president after historic talks
-
Syria's ex-jihadist president meets Trump for historic talks
-
Top US court hears case of Rastafarian whose hair was cut in prison
-
US mediator Kushner and Netanyahu discuss phase two of Gaza truce
-
End to US government shutdown in sight as Democrats quarrel
-
Trump threatens air traffic controllers over shutdown absences
-
US to remove warnings from menopause hormone therapy
-
UK water firm says 'highly likely' behind plastic pellet pollution incident
-
Syria's ex-jihadist president holds historic Trump talks
-
End to record-long US government shutdown in sight
-
France's ex-leader Sarkozy says after jail release 'truth will prevail'
-
Atalanta sack coach Juric after poor start to season
-
Trump threatens $1 billion action as BBC apologises for speech edit
-
Gattuso wants 'maximum commitment' as Italy's World Cup bid on the line
-
Indian capital car blast kills at least eight
-
Deadly measles surge sees Canada lose eradicated status
-
Brazil's Lula urges 'defeat' of climate deniers as COP30 opens
-
Strangled by jihadist blockade, Malians flee their desert town
-
US Supreme Court declines to hear case challenging same-sex marriage
-
'Fired-up' Fritz sees off Musetti in ATP Finals
-
Injured Courtois set to miss Belgium World Cup qualifiers
-
Bulatov, pillar of Russian contemporary art scene, dies at 92
-
Fritz sees off Musetti in ATP Finals
-
US strikes on alleged drug boats kill six more people
-
Sarkozy released from jail 'nightmare' pending appeal trial
-
COP30 has a mascot: the fiery-haired guardian of Brazil's forest
-
The Sudanese who told the world what happened in El-Fasher
-
Three things we learned from the Sao Paulo Grand Prix
-
ASC acquire majority share in Atletico Madrid
-
Ferrari boss tells Hamilton, Leclerc to drive, not talk
Pfizer Covid pill preventing hospitalizations and deaths: White House
Pfizer's anti-Covid pill Paxlovid is helping stave off hospitalizations and deaths amid the United States' latest wave of infections, a senior White House official said Wednesday.
Demand for the treatment has soared, with a four-fold increase over the past month and an estimated 20,000 prescriptions being written every day, White House Covid-19 Response Coordinator Ashish Jha told reporters in a press call.
"I think that is actually a really important reason why, despite this very substantial increase in infections, we have not seen a commensurate increase in deaths," he said.
"We have seen hospitalizations rise, but again, not as much as one would have expected at this point, despite the fact that hospitalizations do lag. When you look at ICU care, the rate of ICU hospital admissions is much lower than what one would expect."
President Joe Biden's administration last month embarked on an aggressive push to expand access to the oral antiviral at tens of thousands of locations across the country.
Omicron's subvariants have driven daily new cases to 94,000, a three-fold increase over the last month, with hospitalizations running at 3,000 a day, and deaths at around 275.
Paxlovid, a combination of two drugs, both taken orally over five days, was shown in a clinical trial to reduce hospitalizations and deaths among at-risk people by almost 90 percent.
Concerns have been raised about "Paxlovid rebound" -- in which some patients clear the virus while on the treatment, but test positive after completing their course.
Jha said the government was studying the issue closely, "but I think it is not leading to people getting particularly sick." The rate of rebound during Paxlovid's clinical trial was two percent, but the dominant variant at the time was Delta.
He also encouraged doctors to adopt a "relatively permissive" approach to prescribing the medicine, given the broad eligibility criteria for being high risk.
"You should not get excessively restrictive, we have plenty of supply right now," he advised doctors.
Jha also urged Congress to quickly provide $22.5 billion in Covid funding so that the government could ensure the supply of next generation Covid vaccines, which are expected to protect against multiple variants.
"Other countries are in conversations with the manufacturers and starting to advance their negotiations," he said, warning Americans could be left behind.
If Congress failed to provide funding, "I think it'd be terrible, I think we'd see a lot of unnecessary loss of life if that were to happen," he said, but the Biden administration would try to find a way to provide vaccines to those at highest risk, he added.
X.Karnes--AMWN